Swiss National Bank Sells 9,600 Shares of Glaukos Co. (NYSE:GKOS)

Swiss National Bank reduced its position in Glaukos Co. (NYSE:GKOS - Free Report) by 9.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 91,000 shares of the medical instruments supplier's stock after selling 9,600 shares during the period. Swiss National Bank owned 0.19% of Glaukos worth $7,234,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in GKOS. Invesco Ltd. raised its position in shares of Glaukos by 45.5% during the 3rd quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier's stock valued at $109,115,000 after acquiring an additional 453,756 shares during the last quarter. Rhenman & Partners Asset Management AB boosted its stake in Glaukos by 236.8% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 320,000 shares of the medical instruments supplier's stock worth $24,080,000 after acquiring an additional 225,000 shares during the last quarter. Fred Alger Management LLC grew its holdings in Glaukos by 9.2% during the third quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier's stock valued at $133,997,000 after purchasing an additional 150,102 shares during the period. Lisanti Capital Growth LLC bought a new stake in Glaukos in the third quarter valued at approximately $6,367,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in Glaukos by 3,894.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 72,978 shares of the medical instruments supplier's stock worth $5,801,000 after purchasing an additional 71,151 shares during the period. Institutional investors own 99.04% of the company's stock.

Insider Buying and Selling

In other news, Director Mark J. Foley sold 4,560 shares of Glaukos stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $92.87, for a total value of $423,487.20. Following the transaction, the director now owns 33,220 shares in the company, valued at approximately $3,085,141.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Alex R. Thurman sold 474 shares of the business's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total transaction of $42,835.38. Following the sale, the chief financial officer now owns 54,916 shares in the company, valued at approximately $4,962,758.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark J. Foley sold 4,560 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $92.87, for a total value of $423,487.20. Following the completion of the transaction, the director now owns 33,220 shares of the company's stock, valued at $3,085,141.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 231,780 shares of company stock worth $21,924,937. Corporate insiders own 6.40% of the company's stock.

Glaukos Stock Up 0.4 %

Shares of NYSE GKOS traded up $0.39 during mid-day trading on Wednesday, hitting $111.36. The company had a trading volume of 397,118 shares, compared to its average volume of 634,114. The company has a current ratio of 5.38, a quick ratio of 4.68 and a debt-to-equity ratio of 0.78. The firm has a 50-day simple moving average of $96.02 and a two-hundred day simple moving average of $85.09. The company has a market capitalization of $5.61 billion, a PE ratio of -38.68 and a beta of 1.08. Glaukos Co. has a one year low of $54.38 and a one year high of $113.97.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The firm had revenue of $85.60 million during the quarter, compared to the consensus estimate of $79.60 million. During the same period in the prior year, the business posted ($0.59) earnings per share. Glaukos's quarterly revenue was up 15.8% compared to the same quarter last year. On average, equities analysts expect that Glaukos Co. will post -2.26 EPS for the current year.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of recent analyst reports. BTIG Research upped their price objective on shares of Glaukos from $107.00 to $112.00 and gave the company a "buy" rating in a research report on Thursday, May 2nd. JPMorgan Chase & Co. raised their price target on Glaukos from $108.00 to $110.00 and gave the stock an "overweight" rating in a research report on Thursday, May 2nd. Citigroup boosted their price objective on Glaukos from $107.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, March 25th. Jefferies Financial Group upgraded shares of Glaukos from a "hold" rating to a "buy" rating and raised their target price for the stock from $84.00 to $125.00 in a report on Monday, May 6th. Finally, Stifel Nicolaus reiterated a "buy" rating and issued a $110.00 price target on shares of Glaukos in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus price target of $108.64.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.